Supplemental Figure 1. Comparison of anti-CD25 antibody and CY.  Panel A.  Mice were either treated with anti-CD25 antibody or CY prior to IL-12/GM-CSF treatment (methods).  The activity indices (proliferating CD8+ T-cell number / CD4+ CD25+ Foxp3+ T-suppressor cell number) for the TDLN and tumors are shown.  Analysis was performed 3 days post-treatment.  Control = blank microspheres, IT = immunotherapy (IL-12/GM-CSF), CY = cyclophosphamide.  Error bars = SE, n = 5-9 per group.  Anti-CD25 + IT group was significantly different from control and IT groups in both the tumor and the TDLN (p < 0.016).  Panel B.  Fold-change in tumor volume between days 0 (treatment) and 21 are shown.  Both CY + IT and anti-CD25 + IT groups were significantly different from control as well as IT groups (p ≤ 0.038).  Error bars = SE, n = 5 – 14 per group.